WHAT IS CLAIMED IS:

1. Use of at least two direct acting antiviral agents (DAAs) in the manufacture of a medicament for treating HCV in a patient, wherein neither interferon nor ribavirin are administered to said patient during said treatment, and said treatment lasts for 16 weeks, and wherein said at least two DAAs comprise:

Compound 1 or a pharmaceutically acceptable salt thereof, and

Compound 2 or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein said patient is infected with HCV genotype 1.

3. The use according to claim 1, wherein said patient is infected with HCV genotype 1a.

4. The use according to claim 1, wherein said patient is infected with HCV genotype 2.

5. The use according to claim 1, wherein said patient is infected with HCV genotype 3.

6. The use according to claim 1, wherein said patient is infected with HCV genotype 4.

7. The use according to claim 1, wherein said patient is infected with HCV genotype 5.

8. The use according to claim 1, wherein said patient is infected with HCV genotype 6.

9. The use according to claim 1, wherein said patient is without cirrhosis.

10. The use according to claim 1, wherein said patient is with compensated cirrhosis.

11. The use according to claim 1, wherein said patient is a treatment-naïve patient.

12. The use according to claim 1, wherein said patient is an interferon non responder.

13. The use according to claim 1, wherein said medicament is formulated for separate administration of said DAAs.

14. The use according to claim 1, wherein said medicament is formulated for combined administration of said DAAs.

15. The use according to any one of claims 1-14, wherein said at least two DAAs is the combination of Compound 1 and Compound 2.

16. The use according to any one of claims 1-14, wherein said at least two DAAs is the combination of Compound 1 and a pharmaceutically acceptable salt of Compound 2.

17. The use according to any one of claims 1-14, wherein said at least two DAAs is the combination of Compound 2 and a pharmaceutically acceptable salt of Compound 1.

18. The use according to any one of claims 1-14, wherein said at least two DAAs is the combination of a pharmaceutically acceptable salt of Compound 1 and a pharmaceutically acceptable salt of Compound 2.